INEOS Ltd - 18 Mar 2026 Form 3 Insider Report for Manchester United plc (MANU)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
31 Mar 2026, 11:15:23 UTC
Prior SEC filing
26 May 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Simon Morland

Key filing fact

INEOS Ltd filed Form 3 for Manchester United plc (MANU) on 31 Mar 2026.

Key facts

  • This page summarizes INEOS Ltd's Form 3 filing for Manchester United plc (MANU).
  • 0 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 31 Mar 2026, 11:15.

Change

  • Previous filing in this sequence was filed on 26 May 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001771044 Primary reporting owner

INEOS Ltd

Relationship
Director, Other*
Address
FORT ANNE, (NO DATA), DOUGLAS, ISLE OF MAN
Signature
/s/ Simon Morland
Signature date
25 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MANU holding

Class A Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
16,188,183
Date
18 Mar 2026
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MANU holding Derivative

Class B Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Class A Ordinary Shares
Underlying amount
33,692,463
Exercise price
$0.000000
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

James A. Ratcliffe, Andy Currie and John Reece (the "Shareholders") collectively have voting and investment power over the securities held by INEOS Limited. Due to that certain letter agreement between the Shareholders with respect to the voting and disposition of the shares in Manchester United plc (the "Issuer"), for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, none of James A. Ratcliffe, Andy Currie and John Reece individually has beneficial ownership over the securities held by INEOS Limited. (cont'd in fn 2)

Footnote F2

(cont'd from fn 1) James A. Ratcliffe, Andy Currie and John Reece each disclaim beneficial ownership over all of the securities in the Issuer held by INEOS Limited and neither the filing of this Form 3 nor any of its contents shall be deemed to constitute an admission by any of James A. Ratcliffe, Andy Currie or John Reece that they are individually the beneficial owners of any of the securities referred to herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F3

Each Class B Ordinary Share is convertible on a one-for-one basis into a Class A Ordinary Share at any time at the option of the holder, and has no expiration date.

SEC remarks

John Reece, who is the chief financial officer of the INEOS group of companies and a director of, and shareholder in, INEOS Limited, and Rob Nevin, who holds certain roles within the INEOS group of companies, are directors of the Issuer and were nominated by INEOS Limited pursuant to a governance agreement dated as of December 24, 2023, and therefore, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, INEOS Limited may be deemed a director by deputization of the Issuer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .